• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2015-2019 年,医疗保险受益人群中丁丙诺啡的种族和民族差异。

Racial And Ethnic Disparities In Buprenorphine Receipt Among Medicare Beneficiaries, 2015-19.

机构信息

Jennifer Miles (

Peter Treitler, Rutgers University.

出版信息

Health Aff (Millwood). 2023 Oct;42(10):1431-1438. doi: 10.1377/hlthaff.2023.00205.

DOI:10.1377/hlthaff.2023.00205
PMID:37782874
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10910625/
Abstract

We examined Medicare Part D claims from the period 2015-19 to identify state and national racial and ethnic disparities in buprenorphine receipt among Medicare disability beneficiaries with diagnosed opioid use disorder or opioid overdose. Racial and ethnic disparities in buprenorphine use remained persistently high during the study period, especially for Black beneficiaries, suggesting the need for targeted interventions and policies.

摘要

我们检查了 2015 年至 2019 年期间的医疗保险 D 部分索赔,以确定在诊断患有阿片类药物使用障碍或阿片类药物过量的医疗保险残疾受益人中,接受丁丙诺啡的州和国家种族和族裔差异。在研究期间,丁丙诺啡的使用在种族和族裔方面仍然存在很大差异,尤其是对于黑人受益人,这表明需要采取有针对性的干预措施和政策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5db/10910625/268608f271f9/nihms-1967304-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5db/10910625/a0940d86ddd8/nihms-1967304-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5db/10910625/4a2ea0786e90/nihms-1967304-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5db/10910625/d585c6ff9434/nihms-1967304-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5db/10910625/842b6820dcd3/nihms-1967304-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5db/10910625/1f1c7f689e22/nihms-1967304-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5db/10910625/268608f271f9/nihms-1967304-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5db/10910625/a0940d86ddd8/nihms-1967304-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5db/10910625/4a2ea0786e90/nihms-1967304-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5db/10910625/d585c6ff9434/nihms-1967304-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5db/10910625/842b6820dcd3/nihms-1967304-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5db/10910625/1f1c7f689e22/nihms-1967304-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5db/10910625/268608f271f9/nihms-1967304-f0006.jpg

相似文献

1
Racial And Ethnic Disparities In Buprenorphine Receipt Among Medicare Beneficiaries, 2015-19.2015-2019 年,医疗保险受益人群中丁丙诺啡的种族和民族差异。
Health Aff (Millwood). 2023 Oct;42(10):1431-1438. doi: 10.1377/hlthaff.2023.00205.
2
Racial/ethnic disparities in timely receipt of buprenorphine among Medicare disability beneficiaries.医疗保险残疾受益人中丁丙诺啡及时获得情况的种族/民族差异。
Drug Alcohol Depend. 2023 Nov 1;252:110963. doi: 10.1016/j.drugalcdep.2023.110963. Epub 2023 Sep 14.
3
Racial Inequality in Receipt of Medications for Opioid Use Disorder.种族不平等与阿片类药物使用障碍药物治疗的获得。
N Engl J Med. 2023 May 11;388(19):1779-1789. doi: 10.1056/NEJMsa2212412.
4
Racial and ethnic disparities in medication for opioid use disorder access, use, and treatment outcomes in Medicare.医疗保险中阿片类药物使用障碍药物获取、使用和治疗结果的种族和民族差异。
J Subst Use Addict Treat. 2024 Feb;157:209271. doi: 10.1016/j.josat.2023.209271. Epub 2023 Dec 21.
5
Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.医疗保险受益人的远程医疗服务的接受情况、阿片类药物使用障碍药物的获得和保留情况,以及在 COVID-19 大流行之前和期间的药物治疗过量情况。
JAMA Psychiatry. 2022 Oct 1;79(10):981-992. doi: 10.1001/jamapsychiatry.2022.2284.
6
Spillover of Medicaid Expansion to Prescribing of Opioid Use Disorder Medications in Medicare Part D.医疗补助扩张对医疗保险处方药中阿片类药物使用障碍药物处方的溢出效应。
Psychiatr Serv. 2022 Apr 1;73(4):418-424. doi: 10.1176/appi.ps.202000824. Epub 2021 Aug 19.
7
Racial and Ethnic Disparities in Meeting MTM Eligibility Criteria Based on Star Ratings Compared with the Medicare Modernization Act.基于星级评定与《医疗保险现代化法案》相比,在符合 MTM 资格标准方面的种族和民族差异。
J Manag Care Spec Pharm. 2018 Feb;24(2):97-107. doi: 10.18553/jmcp.2018.24.2.97.
8
Association Between Buprenorphine Treatment Gaps, Opioid Overdose, and Health Care Spending in US Medicare Beneficiaries With Opioid Use Disorder.美沙酮维持治疗缺口、阿片类药物过量与美国医疗保险受益人群中阿片类药物使用障碍者的医疗保健支出之间的关联
JAMA Psychiatry. 2022 Dec 1;79(12):1173-1179. doi: 10.1001/jamapsychiatry.2022.3118.
9
County-level access to opioid use disorder medications in medicare Part D (2010-2015).医疗保险部分 D 中县级获得阿片类使用障碍药物的情况(2010-2015 年)。
Health Serv Res. 2019 Apr;54(2):390-398. doi: 10.1111/1475-6773.13113. Epub 2019 Jan 21.
10
Racial and Ethnic Disparities in Take-Home Methadone Use for Medicare Beneficiaries With Opioid Use Disorder.患有阿片类物质使用障碍的医疗保险受益人的美沙酮带回家使用情况中的种族和族裔差异。
JAMA Netw Open. 2024 Aug 1;7(8):e2431620. doi: 10.1001/jamanetworkopen.2024.31620.

引用本文的文献

1
Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder by Race and Ethnicity and Insurance Type.按种族、民族和保险类型划分的丁丙诺啡和纳曲酮用于阿片类物质使用障碍的情况
JAMA Netw Open. 2025 Jun 2;8(6):e2518493. doi: 10.1001/jamanetworkopen.2025.18493.
2
Emergency Clinician Buprenorphine Initiation, Subsequent Prescriptions, and Continuous Prescriptions.急诊临床医生启动丁丙诺啡治疗、后续处方及连续处方
JAMA. 2025 Apr 8;333(14):1232-1241. doi: 10.1001/jama.2024.27976.
3
Are gaps in rates of retention on buprenorphine for treatment of opioid use disorder closing among veterans across different races and ethnicities? A retrospective cohort study.

本文引用的文献

1
Twenty-Year Trends in Drug Overdose Fatalities Among Older Adults in the US.美国老年人药物过量致死的二十年趋势
JAMA Psychiatry. 2023 May 1;80(5):518-520. doi: 10.1001/jamapsychiatry.2022.5159.
2
Racial‒Ethnic Disparities of Buprenorphine and Vivitrol Receipt in Medicaid.医疗补助计划中丁丙诺啡和维维酮(Vivitrol)的接受情况存在种族和民族差异。
Am J Prev Med. 2022 Nov;63(5):717-725. doi: 10.1016/j.amepre.2022.05.006. Epub 2022 Jul 6.
3
Expanding Current Approaches to Solve the Opioid Crisis.拓展解决阿片类药物危机的现有方法。
不同种族和族裔的退伍军人在接受丁丙诺啡治疗阿片类药物使用障碍的保留率方面的差距是否在缩小?一项回顾性队列研究。
J Subst Use Addict Treat. 2024 Nov;166:209461. doi: 10.1016/j.josat.2024.209461. Epub 2024 Jul 25.
4
Antiretroviral Therapy Use and Disparities Among Medicare Beneficiaries with HIV.抗逆转录病毒疗法的使用与艾滋病毒医疗保险受益人的差异。
J Gen Intern Med. 2024 Sep;39(12):2196-2205. doi: 10.1007/s11606-024-08847-y. Epub 2024 Jun 12.
JAMA Psychiatry. 2022 Jan 1;79(1):5-6. doi: 10.1001/jamapsychiatry.2021.3136.
4
Disparities in Opioid Overdose Death Trends by Race/Ethnicity, 2018-2019, From the HEALing Communities Study.2018 - 2019年按种族/族裔划分的阿片类药物过量死亡趋势差异,来自“健康社区研究”。
Am J Public Health. 2021 Oct;111(10):1851-1854. doi: 10.2105/AJPH.2021.306431. Epub 2021 Sep 9.
5
Mobile low-threshold buprenorphine integrated with infectious disease services.移动点的丁丙诺啡纳洛酮综合治疗与传染病服务
J Subst Abuse Treat. 2022 Feb;133:108553. doi: 10.1016/j.jsat.2021.108553. Epub 2021 Jun 24.
6
Addressing Racial And Ethnic Disparities In The Use Of Medications For Opioid Use Disorder.解决阿片类药物使用障碍药物使用中的种族和族裔差异。
Health Aff (Millwood). 2021 Jun;40(6):920-927. doi: 10.1377/hlthaff.2020.02261.
7
Overdose deaths from nonprescribed prescription opioids, heroin, and other synthetic opioids in Medicare beneficiaries.医疗保险受益人中因非处方类处方阿片类药物、海洛因及其他合成阿片类药物导致的过量用药死亡情况。
J Subst Abuse Treat. 2021 May;124:108282. doi: 10.1016/j.jsat.2021.108282. Epub 2021 Jan 7.
8
African Americans now outpace whites in opioid-involved overdose deaths: a comparison of temporal trends from 1999 to 2018.非裔美国人现在在阿片类药物相关的过量死亡中超过了白人:1999 年至 2018 年期间时间趋势的比较。
Addiction. 2021 Mar;116(3):677-683. doi: 10.1111/add.15233. Epub 2020 Sep 15.
9
Association of Disability With Mortality From Opioid Overdose Among US Medicare Adults.美国医疗保险成年患者中残疾与阿片类药物过量死亡的关联。
JAMA Netw Open. 2019 Nov 1;2(11):e1915638. doi: 10.1001/jamanetworkopen.2019.15638.
10
Validity of Race and Ethnicity Codes in Medicare Administrative Data Compared With Gold-standard Self-reported Race Collected During Routine Home Health Care Visits.医疗保险行政数据中种族和民族代码的有效性与常规家庭保健就诊期间收集的黄金标准自我报告种族进行比较。
Med Care. 2020 Jan;58(1):e1-e8. doi: 10.1097/MLR.0000000000001216.